CytoDyn Inc. (CYDY) PRO 140 – A Promising Entry in the Treatment of HIV
The upcoming Conference On Retroviruses And Opportunistic Infections, to be held at the Washington State Convention Center in Seattle from February 13-16, 2017, is billed to feature a heavyweight clash between GlaxoSmithKline (NYSE: GSK) and Gilead Sciences (NASDAQ: GILD) for the treatment of HIV patients (http://nnw.fm/05mzG). Gilead is expected to present data from mid-stage Phase II testing of bictegravir, an integrase inhibitor similar to GSK’s dolutegravir. The GSK product, marketed as Tivicay, has enjoyed wide success, gaining approval not only in the U.S. but in Canada and the European Union as well. Its success restored GSK’s dominant position in the…







